ES2668861T3 - Marcadores histológicos para identificar pacientes con carcinoma de pulmón de células no pequeñas para el tratamiento con un fármaco anti EGFR - Google Patents

Marcadores histológicos para identificar pacientes con carcinoma de pulmón de células no pequeñas para el tratamiento con un fármaco anti EGFR Download PDF

Info

Publication number
ES2668861T3
ES2668861T3 ES13829184.4T ES13829184T ES2668861T3 ES 2668861 T3 ES2668861 T3 ES 2668861T3 ES 13829184 T ES13829184 T ES 13829184T ES 2668861 T3 ES2668861 T3 ES 2668861T3
Authority
ES
Spain
Prior art keywords
nsclc
egfr
lung cancer
scc
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13829184.4T
Other languages
English (en)
Spanish (es)
Inventor
Henry Qixiang LI
Mengmeng YANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crown Bioscience Inc Taicang
Original Assignee
Crown Bioscience Inc Taicang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crown Bioscience Inc Taicang filed Critical Crown Bioscience Inc Taicang
Application granted granted Critical
Publication of ES2668861T3 publication Critical patent/ES2668861T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES13829184.4T 2012-07-31 2013-07-31 Marcadores histológicos para identificar pacientes con carcinoma de pulmón de células no pequeñas para el tratamiento con un fármaco anti EGFR Active ES2668861T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
WOPCT/CN2012/079399 2012-07-31
CN2012079399 2012-07-31
PCT/US2013/053091 WO2014028221A1 (en) 2012-07-31 2013-07-31 Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-egfr drug

Publications (1)

Publication Number Publication Date
ES2668861T3 true ES2668861T3 (es) 2018-05-22

Family

ID=50101405

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13829184.4T Active ES2668861T3 (es) 2012-07-31 2013-07-31 Marcadores histológicos para identificar pacientes con carcinoma de pulmón de células no pequeñas para el tratamiento con un fármaco anti EGFR

Country Status (5)

Country Link
US (1) US9921222B2 (https=)
EP (1) EP2879712B1 (https=)
JP (1) JP6324381B2 (https=)
ES (1) ES2668861T3 (https=)
WO (1) WO2014028221A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107073015B (zh) * 2014-09-16 2020-07-21 艾伯维公司 用于治疗吸烟者中的非小细胞肺癌的维利帕尼与卡铂和紫杉醇的组合
CN110520543A (zh) * 2017-03-29 2019-11-29 中美冠科生物技术（太仓）有限公司 确定胃癌对西妥昔单抗敏感性的系统和方法
CN112813164A (zh) * 2021-01-18 2021-05-18 四川省肿瘤医院 Ereg促进nsclc细胞对egfr-tki产生耐药性原因的验证方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5942602A (en) 1997-02-13 1999-08-24 Schering Aktiengessellschaft Growth factor receptor antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
KR20110008112A (ko) 1999-08-27 2011-01-25 제넨테크, 인크. 항-ＥｒｂＢ2 항체 투여 치료 방법
EP1622941A2 (en) 2003-03-20 2006-02-08 ImClone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
CA2560305C (en) 2004-03-19 2016-07-05 Imclone Systems Incorporated Human anti-epidermal growth factor receptor antibody
CA2612183C (en) 2005-06-28 2015-08-11 Genentech, Inc. Egfr and kras mutations
DK1951759T3 (da) 2005-11-12 2010-05-10 Lilly Co Eli Anti-EGFR-antistoffer
WO2008140493A2 (en) 2006-11-21 2008-11-20 The Regents Of The University Of Californina Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof
US7977336B2 (en) 2006-12-28 2011-07-12 Banyu Pharmaceutical Co. Ltd Aminopyrimidine derivatives as PLK1 inhibitors
KR100968591B1 (ko) 2007-06-14 2010-07-08 한국과학기술연구원 약물전달용 폴리포스파젠계 하이드로젤, 그의 제조방법 및그의 용도
US20100009390A1 (en) 2008-05-09 2010-01-14 The Regents Of The University Of California Mutant antibodies with high affinity for egfr
CN102164960A (zh) 2008-09-26 2011-08-24 罗氏格黎卡特股份公司 双特异性抗-egfr/抗-igf-1r抗体
WO2010080463A1 (en) 2008-12-18 2010-07-15 Imclone Llc Antibody humanization
KR101108642B1 (ko) 2009-09-29 2012-02-09 주식회사 녹십자 표피 성장 인자 수용체에 특이적으로 결합하는 항체
CA2777825A1 (en) 2009-10-28 2011-05-19 Abbott Biotherapeutics Corp. Anti-egfr antibodies and their uses
AU2010319322A1 (en) * 2009-11-13 2012-05-31 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
BR112012013148A2 (pt) 2009-12-29 2017-03-21 F Hoffmann - La Roche Ag formulação farmacêutica e uso
JP2011144124A (ja) 2010-01-13 2011-07-28 Fujirebio Inc 活性型ｅｇｆｒ特異抗体
EP2566512A1 (en) 2010-05-04 2013-03-13 Merrimack Pharmaceuticals, Inc. Antibodies against epidermal growth factor receptor (egfr) and uses thereof
WO2011140151A1 (en) 2010-05-04 2011-11-10 Dyax Corp. Antibodies against epidermal growth factor receptor (egfr)
JP5965838B2 (ja) 2010-06-04 2016-08-10 東亞合成株式会社 抗体およびその利用
WO2011156617A2 (en) 2010-06-09 2011-12-15 Aveo Pharmaceuticals, Inc. Anti-egfr antibodies
EP2603527A1 (en) 2010-08-10 2013-06-19 Glycotope GmbH Humanized egfr antibodies
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies

Also Published As

Publication number Publication date
EP2879712A4 (en) 2016-03-16
US9921222B2 (en) 2018-03-20
JP2015527341A (ja) 2015-09-17
EP2879712B1 (en) 2018-04-25
EP2879712A1 (en) 2015-06-10
WO2014028221A1 (en) 2014-02-20
US20150168411A1 (en) 2015-06-18
JP6324381B2 (ja) 2018-05-16

Similar Documents

Publication Publication Date Title
Szyszko et al. PET/CT and PET/MRI in head and neck malignancy
Pellat et al. Clinical and biomarker evaluations of sunitinib in patients with grade 3 digestive neuroendocrine neoplasms
ES3034910T3 (en) Prostate cancer cell lines, gene signatures and uses thereof
AU2007213920B2 (en) Treatment of metastatic breast cancer
ES2661238T3 (es) Biomarcadores y métodos para determinar la eficacia de anticuerpos anti-EGFR en la terapia del cáncer
Moehler et al. An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer
JP2020040959A (ja) 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用
US10085987B2 (en) MCT protein inhibitor-related prognostic and therapeutic methods
ES2668861T3 (es) Marcadores histológicos para identificar pacientes con carcinoma de pulmón de células no pequeñas para el tratamiento con un fármaco anti EGFR
CN104168921B (zh) 用于为抗egfr药物治疗鉴定非小细胞肺癌患者的组织学标志物
JP2017535548A (ja) Ｖｅｇｆアンタゴニストの応答の予測
CN105188742A (zh) Egfr生物标志物用于利用抗egfr试剂治疗胃癌的用途
WO2022259242A1 (en) Combined treatment for cancer
US20150218647A1 (en) Biomarkers for identifying esophageal cancer patients for treatment with an anti-egfr drug
González-Gualda et al. A tumour-promoting senescent secretome triggered by platinum chemotherapy exploits a targetable TGFβR1/Akt-mTOR axis in lung cancer
US12560611B2 (en) Ratio between PLGF and sFLt1 is predictive for neural invasion in patients suffering from pancreatic cancer
Board Ewing Sarcoma Treatment (PDQ®)
Burns et al. MET alterations are enriched in lung adenocarcinoma brain metastases, defining a distinct biologic subtype
WO2019012174A1 (es) pEGFR Y FGFR1 Y/O FGFR4 PARA USO EN LA PREDICCIÓN DE LA RESPUESTA DE LOS PACIENTES A UN TRATAMIENTO DEL CÁNCER DE PULMÓN Y MÉTODO Y KIT BASADOS EN DICHO USO
Sezgin et al. p53 protein accumulation and presence of visceral metastasis are independent prognostic factors for survival in patients with metastatic inflammatory breast carcinoma
Jain et al. CURRENT TREATMENT AND MANAGEMENT OF OROPHARYNGEAL CANCER: A REVIEW
Kemps et al. Alk plus Histiocytosis: A new Clinicopathologic Spectrum highlighting Neurologic Involvement and Responses to Alk Inhibition
ES2734485T3 (es) Células progenitoras hematopoyéticas derivadas de la médula ósea y células progenitoras endoteliales como indicadores pronósticos para el cáncer
CN105407913A (zh) 用于鉴定可用抗egfr药物治疗的食管癌患者的生物标志物
Blaszkowsky et al. Case 13-2011: A 49-Year-Old Man with Adenocarcinoma of the Rectum